Alexander Drilon

In this discussion, Dr. Alexander Drilon, a lung cancer expert from Memorial Sloan Kettering Cancer Center, dives into the ARROS-1 trial of zidesamtinib for ROS1-positive non-small cell lung cancer. He highlights the promising efficacy data, noting the drug's high central nervous system response rates and low neurological side effects. Dr. Drilon explores zidesamtinib's unique mechanism and its potential to redefine first-line treatment, especially for patients resistant to prior TKI therapies. His insights underscore zidesamtinib’s promising role in advancing lung cancer therapy.